2020 is an exciting time to be working for the advancement of psychedelic-assisted therapies as they move into the mainstream. See below for updates (including the creation of a Psychedelic Research Center at Massachusetts General Hospital!) and feel free to reach out with any questions, comments or suggestions.
At the World Economic Forum in Davos, I was heartened to experience the tremendous resonance these topics held for participants in an economics conference. We organized a half-dozen panels, forums and other events with a collection of researchers, advocates, and entrepreneurs including Rick Doblin (MAPS), Rachel Yehuda (Mt.Sinai), Khaliya (Falkora) and David Erritzoe (Imperial College).
Massachusetts General Hospital (MGH) is launching a world-class Psychedelics Research Center and I’m honored and extremely energized to be leading their Advisory Council. It is critical that rigorous science helps to understand and define psychedelic-assisted therapies, which is why I’m so enthusiastic about the proliferation of research centers emerging in the United States and beyond.
MGH is particularly well-positioned to enter the psychedelics research ecosystem. MGH is Harvard University Medical School’s teaching hospital and generally considered to have the top Psychiatry Department in the US, along with world-class imaging facilities and many other relevant resources and faculty. This center is being led by Dr. Jerrold Rosenbaum, the 19-year Chief of MGH’s Psychiatry Department (and a longtime friend) and has Bruce Rosen, the inventor of the fMRI, as it’s Chief Scientific Officer. We’re currently bringing together a community of researchers, supporters, and other advisors to fuel this center – please be in touch to learn more!
In January the Boston Psychedelic Research Group (BPRG) hosted Robin Carhart-Harris, Director of the Centre for Psychedelic Research at Imperial College, for a 150+ attendee presentation about his groundbreaking work leveraging neuroimaging to better understand the effects and potential implications of psychedelics. This event was the most recent installment of the network of researchers, therapists, and supporters brought together through the BPRG. We’re helping other cities bring this community model to their local research ecosystem – be in touch if you’d like to get involved!
I’ve also been very involved with Fantastic Fungi, an amazing film that shines a light on the fascinating but largely-overlooked significance of fungi and also serves as an approachable entry point to understanding the promise of psychedelic-assisted therapies. Learn about the screenings near you here and reach out if you’d like to host or sponsor a screening in your area on March 26, when over 500 theaters from around the world will simultaneously screen the film and an exciting panel discussion for Fantastic Fungi Day!
Please see LINKS below to news you may be interested in and let me know if you have any questions or if I can be of help in any way.
- Psychedelics: Can getting high improve your mental health?
- The FDA Just Expanded Access to MDMA as a Therapy for PTSD
- Compass Pathways reports positive data from psilocybin trial
- FDA grants Breakthrough Therapy Designation to Usona Institute’s psilocybin program for major depressive disorder
- Johns Hopkins Scientists Give Psychedelics the Serious Treatment
- A Hallucinogenic Root is Pitched to Davos Set as Treatment for Opioid Addiction